Loco-Regional Drug Delivery in Cancer Treatment, with Special Reference to Isolation Perfusion

  • S. P. Israëls
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The idea of loco-regional treatment arises from the lack of selectivity of the available chemotherapeutic agents. For most tumours the amount of drug that can be given without unacceptable effects (toxicity) on the normal tissues is not enough. The second idea is that more drug is more effective on tumour response. This is not necessarily always the case in all tumour-drug combinations. The third idea stems from the fact that malignant tumours are different in their metastasizing behaviour. Some tumours metastasize widely through the body in an early stage; others have hardly any metastasizing tendency. The ideal indication for regional therapies therefore remains limited to tumours that have for a prolonged period only a regional spread. Deviation from this concept makes only sense for tumours in a systemically inaccessible location or for palliation.


Soft Tissue Sarcoma Intraperitoneal Chemotherapy Isolate Limb Perfusion Regional Perfusion Regional Delivery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klopp CT, Alford TC, Bateman J et al: Fractionated intra-arterial cancer chemotherapy. Ann Surg 1950 (132):811–832PubMedCrossRefGoogle Scholar
  2. 2.
    Creech OJ, Krementz ET, Ryan RF et al: Chemotherapy of cancer: regional perfusion using an extracorporal circuit. Ann Surg 1958 (148):616–632PubMedCrossRefGoogle Scholar
  3. 3.
    Sullivan RD, Miller E, Sikes MP: Effects of intra-arterial methotrexate-intramuscular citrovorum factor therapy in human cancer. Cancer 1959 (123):1248–1262CrossRefGoogle Scholar
  4. 4.
    Westbury G: Regional cancer chemotherapy. Br J Surg 1967 (54):824–827PubMedCrossRefGoogle Scholar
  5. 5.
    Piccart MJ, Speyer JL, Markman M et al: Intraperitoneal chemotherapy: technical experience at five institutions. Sem One 1985 (XII,3 Suppl 4):90–96Google Scholar
  6. 6.
    Ongerboer de Visser BW, Somers R, Nooyen WH et al: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983 (33):1565–1572PubMedGoogle Scholar
  7. 7.
    Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984 (2):498–504PubMedGoogle Scholar
  8. 8.
    Myers C: The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Sem Oncol 1984 (11):275–284Google Scholar
  9. 9.
    Ozols RF, Locher GY, Doroshow JH et al: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian carcinoma. Cancer Res 1979 (39):3209–3214PubMedGoogle Scholar
  10. 10.
    McVie JG, Dikhoff T, van der Heide J et al: Tissue concentration of platinum after intraperitoneal cisplatin administration in patients. Proc Am Ass Cancer Res 1985 (26):162 (abstr)Google Scholar
  11. 11.
    Briele HA, Djurie M, Jung PT et al: Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985 (45):1885–1889PubMedGoogle Scholar
  12. 12.
    Wile AG, Kar R, Cohen RA et al: The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 1987 (59):695–700PubMedCrossRefGoogle Scholar
  13. 13.
    Howell S, Pfeifle C, Wurg W et al: Intraperitoneal cisplatin with systemic thiosulphate protection. Ann Intern Med 1982(97):845–851PubMedGoogle Scholar
  14. 14.
    Ten Bokkel Huinink WW, Dubbelman R, Aartsen E et al: Experimental and clinical results with intraperitoneal cisplatin. Sem One 1985 (Xll,3 Suppl 4):43–46Google Scholar
  15. 15.
    Ten Bokkel Huinink WW, McVie JG: personal communicationGoogle Scholar
  16. 16.
    Howell SB, Chu BB, Wung WE et al: Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 1981 (67):1161–1170PubMedCrossRefGoogle Scholar
  17. 17.
    Holcenberg J, Anderson T, Ritch P et al: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 1983 (43):1381–1388PubMedGoogle Scholar
  18. 18.
    Lindell B, Aronsen KF, Nosslin B et al: Studies in pharmacokinetics and tolerance of substances temporarily retained in the liver by microsphere embolization. Ann Surg 1978 (187):95–99PubMedCrossRefGoogle Scholar
  19. 19.
    Gyves JW, Ensminger WD, van Harken D et al: Improved regional selectivity of hepatic arterial mitomycin by starch microspheres. Clin Pharmacol Ther 1983 (34):259–265PubMedCrossRefGoogle Scholar
  20. 20.
    Shingelton WW, Parker RT, Matraley S: Abdominal perfusion for cancer chemotherapy with hypothermia and hyperthermia. Surgery 1961 (50):260–265Google Scholar
  21. 21.
    Meister A: Selection modification of glutathione metabolism. Science 1983 (220):472–477PubMedCrossRefGoogle Scholar
  22. 22.
    Sugarbaker PH, Gianola FJ, Speyer JL et al: Prospective randomized trial of intravenous vs intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Surgery 1985 (98):414–421PubMedGoogle Scholar
  23. 23.
    Brenner DE: Intraperitoneal chemotherapy. A review. J Clin Oncol 1986 (4):1135–1147Google Scholar
  24. 24.
    Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Medicine 1975 (293):161–166CrossRefGoogle Scholar
  25. 25.
    Cumberlin R, De Moss E, Lassus M et al: Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 1985 (3):1022–1031PubMedGoogle Scholar
  26. 26.
    Krementz ET, Creech O, Ryan RF et al: An appraisal of cancer chemotherapy by regional perfusion. Ann Surg 1962 (156):417–428PubMedCrossRefGoogle Scholar
  27. 27.
    Cavaliere R, Ciogatto EC, Giovanella BC et al: Selective heat sensitivity of cancer cells. Cancer 1967 (20):1351–1381PubMedCrossRefGoogle Scholar
  28. 28.
    Stehlin JS: Hyperthermic perfusion with chemotherapy for cancer of the extremities. Surg Gynecol Obstet 1969 (129):305–308PubMedGoogle Scholar
  29. 29.
    Stehlin JS, Giovanella BS, de Ipolyi PD et al: Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975 (140):339–348PubMedGoogle Scholar
  30. 30.
    Schraffordt Koops H: Melanoblastoms cutis van de extremiteiten, regionale perfusie en recidief. Thesis, Groningen 1973Google Scholar
  31. 31.
    Schraffordt Koops H, Oldhoff J, van de Ploeg E et al: Some aspects of the treatment of primary malignant melanoma of the extremities by isolated perfusion. Cancer 1977 (39):27–33PubMedCrossRefGoogle Scholar
  32. 32.
    Wieberdink J: Physiological considerations regarding isolation perfusion of the extremities (with special reference to regional chemotherapy of cancer). Monograph delivered on request by the Netherlands Cancer Institute, Amsterdam. Krips Repro, Meppel 1978Google Scholar
  33. 33.
    Benckhuijsen C, Varossieau FJ, Hart AAM et al: Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986 (237):583–588PubMedGoogle Scholar
  34. 34.
    Aigner KR, Walther H, Helling HJ et al: Die isolierte Leberperfusion. Beitr Oncol 1985 (21):48–83. Karger, BaselGoogle Scholar
  35. 35.
    Creech O, Krementz ET, Ryand RF et al: Perfusion treatment of patients with cancer. JAMA 1959 (171):2069–2075CrossRefGoogle Scholar
  36. 36.
    Krementz ET: Regional perfusion. Current sophistication, what next? Cancer 1986 (57):416–432PubMedCrossRefGoogle Scholar
  37. 37.
    Krementz ET, Ryan R, Carter RD et al: Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Milton GW (eds) Cutaneous Melanoma. JB Lippincott, Philadelphia 1984Google Scholar
  38. 38.
    Martijn H, Oldhoff J, Schraffordt Koops H: Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities. J Surg Onc 1982(20):9–13CrossRefGoogle Scholar
  39. 39.
    Martijn H, Oldhoff J, Schraffordt Koops H: Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs. Eur J Cancer 1981 (17):471–476PubMedGoogle Scholar
  40. 40.
    Alberts DS, Chary SY, Chen HSG et al: Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979 (26):73–80PubMedGoogle Scholar
  41. 41.
    Wieberdink J, Benckhuijsen C, Braat RP et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic reactions. Eur J Cancer Clin Oncol 1982 (18):905–910PubMedCrossRefGoogle Scholar
  42. 42.
    McBride CM, Sugarbaker EV, Hickey RC: Prophylactic isolation perfusion as primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975 (182):316–324PubMedCrossRefGoogle Scholar
  43. 43.
    Krementz ET, Carter RD, Sutherland CM et al: The use of regional chemotherapy in the management of malignant melanoma. World J Surg 1979 (3):289–304PubMedCrossRefGoogle Scholar
  44. 44.
    Golomb F, Bomberg J, Dubin N: A controlled study of the survival experience of patients with primary melanoma of the distal extremities treated with adjuvant isolation perfusion. Proceedings of the Second International Conference on the Adjuvant Therapy of Cancer. Grune & Stratton Inc, New York 1979 pp 519–526Google Scholar
  45. 45.
    Sugarbaker EV, McBride CM: Survival and regional disease control after isolation perfusion for invasive stage I melanoma of the extremities. Cancer 1976 (37):188–198PubMedCrossRefGoogle Scholar
  46. 46.
    Klaase JM, Kroon BBR, Benckhuijsen C et al: Regionale isolatieperfusie met cytostatica bij patienten met weke delen tumoren van de ledematen. Submitted for publication, 1987Google Scholar
  47. 47.
    Tonak J, Hohenberger W, Weidner F et al: Hyperthermic perfusion in malignant melanoma; 5 year results. Rec Res Cancer Res 1963 (86):229–238Google Scholar
  48. 48.
    Rege VB, Leone LA, Söderberg jr CH et al: Hyperthermic adjuvant perfusion chemotherapy for stage I melanoma of the extremity. Cancer 1983 (52):2033–2039PubMedCrossRefGoogle Scholar
  49. 49.
    Hanson JA, Simert G, Vang J: The effect of regional perfusion treatment on recurrent melanoma of the extremities. Ada Chir Scand 1977 (143):33–39Google Scholar
  50. 50.
    Bulman AS, Jamieson CW: Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980 (67):660–662PubMedCrossRefGoogle Scholar
  51. 51.
    Jönsson PE, Hafström L, Hugander A: Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Rec Res Can Res 1983 (86) :277–282Google Scholar
  52. 52.
    Kroon BBR, van Geel AN, Benckhuijsen C et al: Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res 1987 (in press)Google Scholar
  53. 53.
    Lejeune FJ, de Loof T, Ewalenko P et al: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Rec Res Can Res 1983 (86) :268–276Google Scholar
  54. 54.
    Rosin RD, Westbury G: Isolated limb perfusion for malignant melanoma. Practitioner 1980 (224):1031–1036PubMedGoogle Scholar
  55. 55.
    Cavaliere R, di Filippo F, Calabro A et al: The role of H.A.P. in the treatment of limb melanoma. Proceedings EORTC Malignant Melanoma Cooperative Group. New perspectives in malignant melanoma. International Symposium, Hamburg 1986Google Scholar
  56. 56.
    Lejeune J: Is isolation perfusion with chemotherapy an improvement in the management of malignant melanoma? In: Oncologisch Kabinet. Ed. Netherlands Cancer Institute, Amsterdam, 1984 pp 71–78Google Scholar
  57. 57.
    Storm FK, Morton DL: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985 (150):32–35PubMedCrossRefGoogle Scholar
  58. 58.
    Vaglini N, Andreola S, Attili A et al: Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities. Tumori 1985 (71):355–359PubMedGoogle Scholar
  59. 59.
    Martijn H, Oldhoff J, Oosterhuis JW et al: Indications for elective groin dissection in clinical stage I patients with malignant melanoma of the lower extremity treated by hyperthermic regional perfusion. Cancer 1983 (52):1526–1534PubMedCrossRefGoogle Scholar
  60. 60.
    Veronesi U, Adamus J, Bandiere DC et al: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremity. Cancer 1982 (49):2420–2430PubMedCrossRefGoogle Scholar
  61. 61.
    Balch CM, Murad TM, Soong SJ et al: A multifractional analysis of melanoma. Ann Surg 1978 (188):732–742PubMedCrossRefGoogle Scholar
  62. 62.
    Ghussen F, Nagel K, Groth W et al: A prospective randomised study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984 (200):764–768PubMedCrossRefGoogle Scholar
  63. 63.
    Martijn H, Schraffordt Koops H, Milton GW et al: Comparison of two methods of treating primary malignant melanoma, Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Cancer 1986 (57):1923–1930PubMedCrossRefGoogle Scholar
  64. 64.
    Franklin HR, Schraffordt Koops H, Oldhoff J et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or more. Submitted for publication, 1987Google Scholar
  65. 65.
    McBride CM: Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974(109):304–308PubMedCrossRefGoogle Scholar
  66. 66.
    Stehlin JS, de Ipolyi PD, Giovanella BC et al: Soft tissue sarcomas of the extremity; multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 1975 (130):643–646PubMedCrossRefGoogle Scholar
  67. 67.
    Lethi PM, Stephens MH, Janoff K et al: Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy.Surg Gynecol Obstet 1986 (162):149–152Google Scholar
  68. 68.
    Krementz ET, Carter RD, Sutherland CM et al: Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977 (185):555–564PubMedCrossRefGoogle Scholar
  69. 69.
    Krementz ET, Muchmore JH: Soft tissue sarcomas: behaviour and management. Adv Surg 1983 (16):147–196PubMedGoogle Scholar
  70. 70.
    Schraffordt Koops H, Eibergen R, Oldhoff J et al: Isolated regional perfusion in the treatment of soft tissue sarcomas of the extremities. Clin Oncol 1976 (2):245–252PubMedGoogle Scholar
  71. 71.
    Cavaliere R, Di Filippo F, Santori FS et al: Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma. Oncology 1987 (44):1–5PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • S. P. Israëls
    • 1
  1. 1.The Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations